Advertisement


Simron Singh, MD, on Neuroendocrine Tumors of the GI Tract: Results from the RADIANT-4 Trial

2016 Gastrointestinal Cancers Symposium

Advertisement

Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors of the GI tract and unknown primary (Abstract 315).



Related Videos

Colorectal Cancer

Eric Francois, MD, on Rectal Cancer: Findings From the ACCORD12 Trial (French Language Version)

Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses in French the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract 490).

Colorectal Cancer

Heinz-Josef Lenz, MD, on Metastatic Colorectal Cancer: Results of the MAVERICC Study

Heinz-Josef Lenz, MD, of the USC Norris Comprehensive Cancer Center, discusses the findings of this phase II study of mFOLFOX6/bevacizumab vs FOLFIRI/bevacizumab with biomarker stratification in patients with metastatic colorectal cancer (Abstract 493). To view the German language version of this newsreel, click here.

Colorectal Cancer

Eric Francois, MD, on Rectal Cancer: Findings From the ACCORD12 Trial

Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract 490). To view the French language version of this newsreel, click here.

Solid Tumors

Dung T. Le, MD, on Noncolorectal GI Cancers: Results From a Phase II Study of Pembrolizumab

Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, reports findings on this agent, which showed promising activity in patients with previously treated progressive, advanced cancer (Abstract 195).

Colorectal Cancer

Krzysztof Bujko, MD, on Rectal Cancer: Results of a Phase III Trial

Krzysztof Bujko, MD, of the Maria Skłodowska Curie Memorial Cancer Centre, discusses the results of a multicenter Polish study on neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancer (Abstract 489).

Advertisement

Advertisement



Advertisement